Why the study?
To examine clinical characteristics and outcomes in women and men referred for advanced heart failure therapies such as left ventricular assist device or heart transplantation.
Do clinical characteristics and outcomes differ between women and men referred for advanced heart failure therapies?
Do clinical characteristics and outcomes differ between women and men referred for advanced heart failure therapies?
Women referred for advanced heart failure therapies present with less deranged hemodynamics, experience shorter waitlist times for heart transplantation, and have higher survival rates compared to men.
Answers are grounded in this paper and cite their sources.
Women referred for advanced HF therapies had less deranged hemodynamics and higher HTx rates; leaves open whether referral patterns differ by sex.
Objective To examine clinical characteristics and outcomes in women and men referred for advanced heart failure (HF) therapies such as left ventricular assist device (LVAD) or heart transplantation (HTx). Design: A retrospective study of 429 (23% women) consecutive adult HF patients not on inotropic or mechanical circulatory support with left ventricular ejection fraction ≤45% referred for assessment of advanced HF therapies at a single tertiary institution between 2002 and 2016. Clinical characteristics and outcomes were compared in women and men, and all patients underwent right heart catheterization (RHC). Results: At evaluation, women were younger than men (48 ± 13 vs. 51 ± 12 years, p = .02), and less likely to have ischemic cardiomyopathy. There were no significant differences in NYHA class, contemporary HF therapy use, or physical examination findings, except for lower jugular vein distension and body surface area in women. On RHC, women had lower cardiac filling pressures, but similar pulmonary vascular resistance and cardiac index. Peak oxygen uptake from cardiopulmonary exercise testing was similar in both sexes. At total follow-up time, there were 164 deaths (21% vs. 44%, p < .0001), 46 LVADs (3% vs. 13%, p = .005), 110 HTxs (32% vs. 25%, p = .15), and 82 HTxs without requiring LVAD (29% vs. 16%, p = .03) in women and men. The time from RHC to HTx (±LVAD) was significantly shorter in women compared to men. Female sex was significantly associated with higher survival independent of time-trend, age, and comorbidities. Conclusion: At evaluation, hemodynamics were less deranged in women. A higher proportion of women received HTx, their waitlist time was shorter, and survival greater.
No takes yet. Share an insight, caveat, or question.
Vishram‐Nielsen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: